Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab [6]

Annals of Oncology

Volumn 18, Issue 5, 2007, Pages 963-964

  Helbling, Daniel ^a   Borner, M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CETUXIMAB; CLEMASTINE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PANITUMUMAB; RANITIDINE; STEROID;

ADULT; AGITATION; CASE REPORT; COLON CANCER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; HUMAN; LETTER; MALE; METASTASIS; MONOTHERAPY; PATIENT MONITORING; PATIENT SAFETY; PRIORITY JOURNAL; SIDE EFFECT; URTICARIA;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; HUMANS; HYPERSENSITIVITY; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 34447340247     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm130     Document Type: Letter

References (2)

1. Erbitux® (cetuximab) prescribing information. ImClone Systems, Inc. 2006.
2. Van Cutsem E, Peeters M, Siena S et al. Panitumumab significantly improves progression-free survival in patients with metastatic colorectal cancer. Ann Oncol 2006; 17 (Suppl 6): Vi27 (Abst 0-027).